Intraoperative Ultrasound-Guided Cryoablation of Renal Tumors

Publication
Article
OncologyONCOLOGY Vol 12 No 11
Volume 12
Issue 11

Renal cancer occurs in nearly 10 of every 100,000 people in the United States and in approximately 45 of every 100,000 of those over 65 years of age. Standard treatment is open surgery, often involving total removal of the tumor along with the kidney. However, a study in the September issue of the Journal of Ultrasound in Medicine reports that ultrasound-guided renal cryoablation is a feasible technique for treating renal malignancies while still preserving the renal parenchyma.

Renal cancer occurs in nearly 10 of every 100,000 people in the United States and in approximately 45 of every 100,000 of those over 65 years of age. Standard treatment is open surgery, often involving total removal of the tumor along with the kidney. However, a study in the September issue of the Journal of Ultrasound in Medicine reports that ultrasound-guided renal cryoablation is a feasible technique for treating renal malignancies while still preserving the renal parenchyma.

Sparing Renal Tissue

Harry G. Zegel, MD, and coauthors from theAllegheny University Hospitals in Pennsylvania and Urology Specialists of Coastal Georgia write, "Recent advances in cross-sectional imaging (ultrasound, MRI, CT) have led to increased detection of small, asymptomatic renal tumors. Also, in selected cases, patients undergoing partial nephrectomy have been reported to have rates of survival similar to those of patients undergoing radical nephrectomy. This has led some physicians to question the need for radical nephrectomy in patients with small lesions. While partial nephrectomy spares the maximal amount of functioning renal tissue, and often eliminates or postpones the need for dialysis, this technique is associated with risks. Hence, better kidney tissue-sparing techniques may be of benefit in selected patients."

The study examined the feasibility of using ultrasound-guided cryosurgery to treat selected patients with renal malignancy by studying the technique in six patients with renal tumors.

Benefits of Intraoperative Ultrasonography

In the study, intraoperative ultrasonography accurately delineated tumor size, cryoprobe placement, and depth of freezing in all patients. In addition, intraoperative ultrasonography identified a total of nine additional lesions in three patients that had not been detected by preoperative imaging. The patients have been followed with clinical and laboratory assessments, as well as MRI or CT imaging, and all were tumor-free 3 to 22 months, postoperatively.

In conclusion, the authors write, "we conclude that cryoablation with intraoperative ultrasonographic guidance is a promising new technique for treating renal masses while preserving renal parenchyma and function. Long-term follow-up in a larger series of patients with biopsy-proved lesions is necessary to determine the true efficacy and safety of this procedure."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content